Co-relation of SARS-CoV-2 related 30-d mortality with HRCT score and RT-PCR Ct value-based viral load in patients with solid malignancy

Table 2 Primary and Secondary outcomes by potential prognostic variables (n = 123), n (%)

	Admitted to ICU	Met composite endpoint	Required mechanical ventilation	Died
Total (n = 123)	20 (16.2)	30 (24.3)	10 (8.1)	18 (14.6)
Age, yr
< 65 (n = 91)	18 (19.7)	22 (22.2)	9 (9.9)	16 (17.6)
65-74 (n = 25)	1 (4)	5 (20)	1 (4)	1 (4)
≥ 75 (n = 7)	1 (14.3)	3 (42.8)	0	1 (14.3)
Sex
Male (n = 59)	6 (10.2)	11 (18.6)	3 (5)	5 (8.5)
Female (n = 64)	14 (21.8)	19 (29.7)	7 (10.9)	13 (20.3)
Number of comorbidities
0 (n = 54)	6 (11.1)	9 (16.7)	0	4 (7.4)
1 (n = 32)	5 (15.6)	11 (34.4)	4 (12.5)	5 (15.6)
≥ 2 (n = 37)	9 (24.3)	10 (27)	6 (16.2)	9 (24.3)
Type of malignancy
Thorax (n = 10)	1 (10)	2 (20)	1 (10)	1 (10)
GIT (n = 9)	5 (55.5)	6 (66.6)	3 (33.3)	4 (44.5)
HPB (n = 40)	8 (20)	14 (35)	4 (10)	7 (17.3)
GUT (n = 49)	5 (10)	7 (14.2)	2 (4)	5 (10)
Others (n = 15)	1 (6.7)	1 (6.7)	0	1 (6.7)
Cancer status
Remission or no evidence of disease (n = 8)	0	2 (25)	0	0
Present, stable, or responding to treatment (n = 66)	6 (9.9)	9 (13.6)	5 (7.6)	5 (7.6)
Present, progressive disease unknown (n = 49)	14 (28.6)	19 (38.7)	5 (10)	13 (26.5)
ECOG performance status
0 or 1 (n = 90)	0	10 (11.1)	0	0
2 (n = 18)	2 (11.1)	5 (27.7)	2 (11.1)	4 (22.2)
≥ 3 (n = 15)	15 (100)	15 (100)	8 (53.3)	14 (93.3)
Type of anticancer therapy
None in the 4 wk before COVID-19 diagnosis (n = 14)	6 (42.5)	8 (57.1)	3 (21.4)	5 (35.7)
Non-cytotoxic therapy targeted therapy/endocrine therapy (n = 9)	2 (22.2)	5 (55.5)	1 (11.1)	2 (22.2)
Immunotherapy (n = 3)	0	0	0	0
Cytotoxic systemic therapy (n = 90)	11 (12.2)	16 (17.7)	6 (6.7)	10 (11.1)
External beam radiotherapy (n = 7)	1 (14.3)	1 (14.3)	0	1 (14.3)
Recent surgery
None in the 4 wk before COVID-19 diagnosis (n = 113)	19 (16.8)	28 (24.8)	9 (8)	17 (15)
Yes (n = 10)	1 (10)	2 (20)	1 (10)	1 (10)
RT-PCR Test (viral load)
Mild (n = 49)	5 (10.2)	8 (16.3)	3 (6.1)	5 (10.2)
Moderate (n = 30)	5 (16.7)	9 (30)	4 (13.3)	5 (16.7)
High (n = 44)	10 (22.7)	13 (29.5)	3 (6.8)	8 (18.1)
HRCT Score
Mild (n = 77)	7 (9)	13 (16.9)	0	5 (6.5)
Moderate (n = 38)	7 (18.4)	11 (28.9)	4 (10.5)	7 (18.4)
Severe (n = 8)	6 (75)	6 (75)	6 (75)	6 (75)
Treatment of COVID-19
Hydroxychloroquine (HCQ) alone, azithromycin alone or with combination HCQ/azithromycin/ivermectin (n = 22)	1 (4.5)	3 (13.6)	0	1 (4.5)
+ Steroids (n = 36)	4 (11.1)	8 (22.2)	2 (5.6)	4 (11.1)
+ Remdesivir (n = 29)	8 (27.6)	11 (37.9)	4 (13.8)	7 (24.1)
+ Tocilizumab (n = 3)	1 (33.3)	1 (33.3)	0	1 (33.3)
+ Plasma therapy (n = 11)	6 (54.4)	7 (63.6)	4 (36.6)	4 (36.6)
Neither (n = 22)	0	0	0	0

GIT: Gastrointestinal tract; HPB: Hepatopancreatobiliary; GUT: Genitourinary tract; COVID-19: Coronavirus disease 2019; ECOG: Eastern Cooperative Oncology Group; ICU: Intensive care unit.